HealthDay: 'Neuroprotectant' drug could boost outcomes after stroke
UC's Broderick comments on study
A new study found using a "neuroprotectant" drug alongside the standard surgical removal of a blood clot may reduce the risk of death and disability following a stroke.
Researchers presenting data at the International Stroke Conference reported the medication, called ApTOLL, protects brain tissue from continuing damage by cooling down inflammation.
More than 150 people who had an ischemic stroke were enrolled in the study in France and Spain, either receiving ApTOLL at two different doses or a placebo medication in addition to mechanical blood clot removal.
The patients who received the higher dose of ApTOLL were four times less likely to die from stroke compared to the patients who received a placebo.
Joseph Broderick, MD, professor in UC’s Department of Neurology and Rehabilitation Medicine in the College of Medicine, director of the UC Gardner Neuroscience Institute and a UC Health physician, commented on the study for HealthDay. He said the drug needs to be tested more thoroughly before becoming a standard of care.
"The data warrants further study in a phase 3 study, but differences seen in this trial may be due to small number of patients and imbalances in factors related to outcome," Broderick said, adding that a much larger trial would be needed to confirm the findings.
Featured photo at top of Dr. Broderick. Photo/Joseph Fuqua II/University of Cincinnati
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.